Global Alpha Capital Management Ltd. Purchases 5,646 Shares of Vericel Corporation $VCEL

Global Alpha Capital Management Ltd. raised its position in Vericel Corporation (NASDAQ:VCEL) by 11.9% during the second quarter, Holdings Channel reports. The firm owned 52,983 shares of the biotechnology company’s stock after purchasing an additional 5,646 shares during the period. Global Alpha Capital Management Ltd.’s holdings in Vericel were worth $2,254,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Ameritas Advisory Services LLC bought a new position in Vericel during the second quarter worth $30,000. CWM LLC grew its holdings in Vericel by 101.3% during the 2nd quarter. CWM LLC now owns 1,379 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 694 shares during the period. AlphaQuest LLC bought a new position in shares of Vericel in the 2nd quarter worth about $60,000. Gagnon Securities LLC acquired a new position in shares of Vericel in the 1st quarter valued at about $137,000. Finally, US Bancorp DE lifted its stake in shares of Vericel by 29.9% in the 1st quarter. US Bancorp DE now owns 3,071 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 706 shares during the period.

Vericel Stock Performance

Shares of VCEL opened at $38.94 on Friday. Vericel Corporation has a 52 week low of $29.24 and a 52 week high of $63.00. The stock has a 50 day moving average price of $33.78 and a two-hundred day moving average price of $37.73. The firm has a market capitalization of $1.96 billion, a P/E ratio of 324.53 and a beta of 1.41.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Thursday, November 6th. The biotechnology company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.12. The business had revenue of $67.50 million during the quarter, compared to the consensus estimate of $64.57 million. Vericel had a return on equity of 2.47% and a net margin of 2.85%.Vericel’s revenue was up 16.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.02) earnings per share. Vericel has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Vericel Corporation will post 0.14 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on VCEL shares. Canaccord Genuity Group decreased their target price on Vericel from $61.00 to $58.00 and set a “buy” rating for the company in a research note on Friday, August 1st. Weiss Ratings reissued a “sell (d+)” rating on shares of Vericel in a research report on Wednesday, October 8th. Zacks Research upgraded Vericel from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 14th. BTIG Research downgraded Vericel from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 17th. Finally, Wall Street Zen raised Vericel from a “hold” rating to a “buy” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Vericel presently has a consensus rating of “Moderate Buy” and a consensus target price of $58.40.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.